US28106W1036 - Common Stock
EDITAS MEDICINE INC
NASDAQ:EDIT (5/8/2024, 11:23:00 AM)
5.14
-0.54 (-9.51%)
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 226 full-time employees. The company went IPO on 2016-02-03. The firm is focused on developing transformative gene editing medicines to treat a range of serious diseases. The company has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cas12a), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The company is engaged in the development of in vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, EDIT-301, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta-thalassemia (TDT).
EDITAS MEDICINE INC
11 Hurley St
Cambridge MASSACHUSETTS 02141
P: 16174019000
CEO: James C. Mullen
Employees: 226
Website: https://www.editasmedicine.com/
EDIT stock results show that Editas Medicine missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it...
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases...
Here you can normally see the latest stock twits on EDIT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: